ArticleAsia Pacific allergy2026
Evaluating montelukast-second-generation antihistamine combinations versus monotherapy in allergic rhinitis: A network meta-analysis.
Article in Asia Pacific allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is an atopic condition affecting over 400 million people worldwide, impairing quality of life and often leading to complications such as asthma and sinusitis. Montelukast, a leukotriene receptor antagonist, is often used in combination with second-generation antihistamines (sgAHs) to enhance symptom control. However, the relative efficacy of different montelukast-sgAH combinations remains unclear. Objective: To evaluate and compare the efficacy of montelukast combined with various sgAHs versus montelukast monotherapy in patients with AR. Methods: Randomized controlled trials (RCTs) comparing montelukast-sgAH combinations to montelukast alone were identified from 5 electronic databases up to 2025. Outcomes included Total Nasal Symptom Score (TNSS; 0-12), Daytime and Nighttime Nasal Symptom Scores (DNSS, NNSS; 0-3), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ; 0-6). Risk of bias (RoB) was assessed using Cochrane RoB 2.0. A frequentist network meta-analysis with subgroup analysis and meta-regression was performed using RStudio and Jeffreys's Amazing Statistics Program. Results: Seventeen RCTs involving 2,655 participants were included. For TNSS improvement, montelukast + desloratadine combination is significantly better than monotherapy in adults (mean difference [MD] = -0.92 [-1.15 to -0.69]) and children (MD = -1.95 [-3.46 to -0.44]). Effects on RQLQ and DNSS were inconsistent, while NNSS improved with montelukast-levocetirizine ( Conclusion: Montelukast-sgAH combinations may improve symptoms over monotherapy, especially with desloratadine in both adults and children. However, variability across outcomes and high heterogeneity warrant cautious interpretation and further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.